This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in
the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a
specific MYD88 gene mutation.
This research study involves an experimental drug combination of targeted therapies.
The names of the study drugs involved in this study are:
- Venetoclax
- ibrutinib